Related Experiment Video
Updated: Jul 4, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Bendamustine as a model for the activity of alkylating agents
Christos Apostolopoulos1, Leandro Castellano, Justin Stebbing
1Imperial College School of Medicine, Department of Medical Oncology, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK.
Bendamustine hydrochloride, an alkylating agent, shows promise for resistant hematological cancers. Further trials are needed to confirm its role in front-line regimens for lymphomas and other malignancies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Personalized chemotherapy has yielded disappointing results.
- Alkylating agents are a versatile class of anticancer drugs.
- Bendamustine hydrochloride is a newer alkylating agent with diverse actions.
Purpose of the Study:
- To evaluate the efficacy of bendamustine hydrochloride in various cancers.
- To explore its potential in resistant or refractory hematological diseases.
Main Methods:
- Clinical trials of bendamustine hydrochloride as monotherapy.
- Combination therapy with standard of care treatments.
- Evaluation in hematological malignancies and solid tumors.
Main Results:
- Bendamustine hydrochloride demonstrates a role in resistant/refractory hematological disease.
- US FDA approved bendamustine hydrochloride for chronic lymphocytic leukemia in 2008.
Conclusions:
- Bendamustine hydrochloride is a valuable option for specific hematological cancers.
- Ongoing trials will determine its broader application in front-line cancer treatment regimens.
Related Concept Videos
Drugs that Destabilize Microtubules
Antifungal Agents
Spontaneous and Induced Mutations
Mutagenicity and Carcinogenicity
Drugs that Stabilize Microtubules
Physical Properties of Amines
